IPM 005B

A PHASE I/II SINGLE-CENTRE DOUBLE-BLINDED, RANDOMIZED STUDY
OF THE SAFETY AND TOLERABILITY OF DAPIVIRINE VAGINAL
MICROBICIDE GEL (TMC 120 GEL-002) VS. HEC-BASED UNIVERSAL
PLACEBO GEL IN HEALTHY HIV-NEGATIVE WOMEN

SPONSOR:

International Partnership for Microbicides
1010 Wayne Avenue, Suite 1450
Silver Spring, MD 20910 U.S.A.

Final 2.0
March 30, 2006
PROTOCOL SYNOPSIS

IPM 005B

A PHASE I/II SINGLE-CENTRE DOUBLE-BLINDED, RANDOMIZED STUDY OF THE SAFETY AND TOLERABILITY OF DAPIVIRINE VAGINAL MICROBICIDE GEL (TMC 120 GEL-002) VS. HEC-BASED UNIVERSAL PLACEBO GEL IN HEALTHY HIV-NEGATIVE WOMEN

DESIGN: This study is a double blinded, randomized, two-arm, single-site trial in Belgium to assess the local safety on vulval and cervicovaginal mucosa, systemic toxicity, and tolerability of twice daily use of Dapivirine Gel-002 in healthy HIV-negative women for 42 days. Participants will be randomized to receive either 0.02% (200 µg/mL) Dapivirine Gel-002 or an HEC-based universal placebo gel. All participants will receive condoms. Acceptability and compliance with the use of the gel will be assessed. Participants will be monitored on Days 7, 28 and 42 for safety, tolerability and compliance.

STUDY POPULATION: Healthy, HIV-negative women aged ≥18 and ≤ 50 living in Belgium with no clinically detectable genital abnormality (including vulval, vaginal, cervical, and/or perineal ulcer and/or lesion), no abnormal or grossly bloody Pap smear, nor internal vaginal warts.

SAMPLE SIZE: Approximately 36 participants will be enrolled.

REGIMEN: At entry, participants will be randomized 2:1 to one of the following study arms for 42 days of treatment:

Arm A: 0.02% Dapivirine Gel-002 (67 % of participants)
Arm B: HEC-based placebo gel (33 % of participants)

Randomization will be double blinded. Participants will self-apply 2.5 mL of study gel with pre-filled applicators b.i.d. (shortly after awakening and in the evening approximately 12 hours after morning application). The first gel application will be applied by the participant at the site under the supervision of a clinical staff member (direct observation is optional). Participants will remain in the clinic under observation for 30 minutes after the first application. Application of the study gel will continue twice daily, regardless of sexual activity, for 42 days including during menses. However, failure to apply the gel during menses will not result in a protocol violation. Participants will be instructed not to use the gel rectally. All participants will be given condoms.
Treatment for urinary and genital infections (except HPV) will be provided from screening through Day 56.

**STUDY DURATION:** It is anticipated that the study will be accrued in approximately 3-4 months. Participants’ total participation will be 28 days in screening and 56 days of follow-up.

**PRIMARY OBJECTIVES:**

- To assess the local safety and tolerability on vulval and cervicovaginal mucosa of Dapivirine Gel-002 when applied twice daily for 42 days at a concentration of 0.02% compared to an HEC-based “universal” placebo.

- To assess the systemic safety of Dapivirine Gel-002 when applied twice daily for 42 days at a concentration of 0.02% compared to an HEC-based “universal” placebo.

**SECONDARY OBJECTIVES:**

- To assess the acceptability of Dapivirine Gel-002 when applied twice daily for 42 days at a concentration of 0.02% compared to an HEC-based “universal” placebo.

- To assess compliance to Dapivirine Gel-002 when applied twice daily for 42 days at a concentration of 0.02% compared to an HEC-based “universal” placebo in HIV-negative women.